# Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants

> **NCT02325791** · PHASE3 · COMPLETED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 1177 (actual)

## Conditions studied

- Respiratory Syncytial Virus Infections

## Interventions

- **DRUG:** Suptavumab 30 mg/kg
- **DRUG:** Placebo Matched to Suptavumab
- **DRUG:** Suptavumab 30 mg/kg- 1 Dose
- **DRUG:** Suptavumab 30 mg/kg - 2 Doses

## Key facts

- **NCT ID:** NCT02325791
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-21
- **Primary completion:** 2017-07-05
- **Final completion:** 2017-09-26
- **Target enrollment:** 1177 (ACTUAL)
- **Last updated:** 2018-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02325791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02325791, "Study to Evaluate the Efficacy and Safety of Suptavumab (REGN2222) for the Prevention of Medically Attended RSV (Respiratory Syncytial Virus) Infection in Preterm Infants". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02325791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*